Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetrelimab + Apalutamide in mCRPC
NCT03551782Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2018
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
Phase 1, open-label trial of cetrelimab in metastatic castration-resistant prostate cancer (mCRPC) (5 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants With Adverse Events and Percentage of Participants with Prostate-Specific Antigen Response at Week 12. Started Jun 2018; status: completed.
02
Drugs
cetrelimab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03551782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03551782.